Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases.
It has been believed that acute lung injury in influenza virus infections is caused by a virus-induced cytopathy; viruses that have multiplied in the upper respiratory tract spread to lung tissues along the lower respiratory tract. However, some experimental and clinical studies have suggested that the pathogenesis of acute lung injury in influenza virus infections is associated with excessive host response including a cell-mediated immune reaction. During the pandemic H1N1 2009 influenza A virus infections in Korea, we experienced a dramatic effect of immune-modulators (corticosteroids) on the patients with severe pneumonia who had significant respiratory distress at presentation and those who showed rapidly progressive pneumonia during oseltamivir treatment. We also found that the pneumonia patients treated with corticosteroids showed the lowest lymphocyte differential and that the severity of pneumonia was associated with the lymphocyte count at presentation. From our findings and previous experimental and clinical studies, we postulated that hyperactive immune cells (T cells) may be involved in the acute lung injury of influenza virus infections, using a hypothesis of 'protein homeostasis system'; the inducers of the cell-mediated immune response are initially produced at the primary immune sites by the innate immune system. These substances reach the lung cells, the main target organ, via the systemic circulation, and possibly the cells of other organs, including myocytes or central nerve system cells, leading to extrapulmonary symptoms (e.g., myalgia and rhabdomyolysis, and encephalopathy). To control these substances that may be possibly toxic to host cells, the adaptive immune reaction may be operated by immune cells, mainly lymphocytes. Hyperimmune reaction of immune cells produces higher levels of cytokines which may be associated with acute lung injury, and may be controlled by early use of immune-modulators. Early initiation and proper dosage of immune-modulators with antiviral agents for severe pneumonia patients may reduce morbidity and prevent progressive fatal pneumonia.
Lee
Kyung-Yil
KY
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. leekyungyil@catholic.ac.kr
Rhim
Jung-Woo
JW
Kang
Jin-Han
JH
D055371:Acute Lung Injury / Q000150:complications* / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification; D007251:Influenza, Human / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D013601:T-Lymphocytes / Q000276:immunology*
D000276:Adjuvants, Immunologic
Crit Care Med. 2003 Nov;31(11):2684-92
14605542
Viral Immunol. 2007 Summer;20(2):243-9
17603841
Expert Rev Anti Infect Ther. 2008 Aug;6(4):509-21
18662117
J Chin Med Assoc. 2005 Jan;68(1):4-10
15742856
Proc Soc Exp Biol Med. 1974 May;146(1):78-84
4827270
Crit Care Med. 2009 May;37(5):1594-603
19325471
Int J Antimicrob Agents. 2010 May;35(5):421-30
20185273
Immunol Rev. 2008 Oct;225:68-84
18837776
Avian Dis. 2007 Mar;51(1 Suppl):242-9
17494560
Lancet. 1957 Dec 7;273(7006):1164-5
13492601
Br J Hosp Med. 1978 Apr;19(4):344, 346-50, 352
656670
Cell. 2009 Feb 6;136(3):402-10
19203576
Cell Host Microbe. 2010 Feb 18;7(2):103-14
20159617
Emerg Infect Dis. 2009 Jan;15(1):19-23
19116044
Nature. 2009 Jun 18;459(7249):931-9
19525932
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
AIDS. 2010 Sep 10;24(14):2292-4
20639725
Arch Intern Med. 2008 May 26;168(10):1034-46
18504331
Clin Microbiol Rev. 2007 Apr;20(2):243-67
17428885
Med Hypotheses. 2006;67(4):848-55
16759810
J Virol. 2001 Jul;75(13):5921-9
11390593
Pediatr Pulmonol. 2003 Oct;36(4):290-4
12950040
Lab Anim Sci. 1992 Jun;42(3):222-32
1320150
Crit Care Med. 2009 May;37(5):1800-3
19373049
Lancet. 2003 May 24;361(9371):1767-72
12781535
N Engl J Med. 2009 Aug 13;361(7):680-9
19564631
BMC Pediatr. 2010 Jul 06;10:48
20604923
Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92
17213831
Cell Microbiol. 2007 Jul;9(7):1641-6
17506818
Transfus Apher Sci. 2007 Aug;37(1):103-7
17765663
Med Hypotheses. 2007;69(3):642-51
17337130
Acta Virol. 1973 Jul;17(4):293-7
4148208
J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):76-85
20188830
J Virol. 2000 Jul;74(13):6105-16
10846094
Infect Immun. 1977 Jan;15(1):221-9
832899
Nat Med. 2006 Oct;12(10):1203-7
16964257
Clin Exp Immunol. 2010 Sep;161(3):397-406
20560984
Pediatr Pulmonol. 2006 Mar;41(3):263-8
16437541
Autoimmun Rev. 2009 May;8(6):525-8
19186222
Am J Emerg Med. 2008 Jul;26(6):711-5
18606328
Drug Chem Toxicol. 1999 Feb;22(1):91-128
10189573
Clin Infect Dis. 2010 Mar 15;50(6):850-9
20136415
Transplantation. 2009 Jul 15;88(1):1-6
19584672
EMBO Mol Med. 2009 May;1(2):92-8
20049709
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12479-81
17640882
J Basic Clin Physiol Pharmacol. 2009;20(2):99-125
19662715
Science. 2009 Jul 24;325(5939):484-7
19574347
PLoS Med. 2009 Jun 23;6(6):e1000091
19554084
Immunology. 1988 Mar;63(3):349-53
2832312
Intensive Care Med. 2010 Jan;36(1):33-41
19924393
Scand J Infect Dis. 2005;37(6-7):471-5
16012007
J Gen Virol. 2005 Oct;86(Pt 10):2823-2830
16186238
PLoS One. 2008 Aug 21;3(8):e2985
18716658